Does “growth-1295” identify the compound?
I wouldn’t use that search phrase as a precise chemical name. With CJC-1295, “with DAC” matters: DAC is an addition that attaches it to albumin, a blood protein, so it lasts longer. The FDA review treats DAC and non-DAC forms as different active ingredients.
A familiar-looking name can hide an important difference.
The human hormone findings come from the long-acting form. FDA found no human studies of the non-DAC forms it assessed. I’d want the form spelled out before deciding which paper belongs in the discussion.
Does half-life tell me when I’ll feel better?
No. Half-life describes how quickly the amount of a substance falls in the body. The long-acting CJC-1295 study measured that, along with hormone changes. It didn’t establish a countdown to better sleep or recovery.
I keep the two questions separate: how long something stays around, and whether it helps. Neither a half-life nor a hormone rise supplies a personal dosing schedule. That decision belongs with a prescriber assessing the person.
Does a hormone rise mean it’s safe?
It doesn’t. A blood measurement can tell us that the hormone system responded while leaving long-term safety unanswered. “It works on the hormone” and “it improves health safely” are different claims, with different evidence needed.
A changed blood result isn’t an all-clear.
The review of growth hormone stimulators raises blood-sugar and insulin-sensitivity concerns. Insulin sensitivity means how readily the body responds to insulin. Those concerns stay relevant even when a hormone result looks interesting.
Do the separate studies prove the pair helps?
No. The pairing has a rationale from work on hormone signals in cells. That experiment wasn’t a controlled human trial of this fixed combination. Separate studies of the ingredients can’t supply one after the fact.
I’ve kept the longer pairing discussion on its own page. It explains why people are interested, where the sleep and recovery hopes outrun the evidence, and how prescription access fits into a different part of the conversation.
Did withdrawal mean FDA clearance?
No. FDA’s page current as of April 22, 2026 lists CJC-1295 as nominated but withdrawn, with safety concerns still beside it. The page gives no individual withdrawal date. Withdrawal isn’t clearance, approval or a move to Category 1.
A withdrawn request doesn’t put “approved” on the label.
Ipamorelin acetate also appears in that table and remains in the Category 2 safety-concern group under the 503B outsourcing-facility policy. Neither ingredient is FDA-approved. And compounded medicines don’t have FDA approval, even when prescribed.